Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of Tazemetostat in Relapsed or Refractory Follicular Lymphoma with EZH2 Mutation in Japan
jRCT2001220001Recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tazemetostat in follicular lymphoma (FL), sponsored by Eisai Co., Ltd. Primary endpoints: Number of participants with adverse drug reactions and Number of participants with serious adverse drug reactions. Started Aug 2021; status: recruiting.
02
Drugs
tazemetostat
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on jRCT2001220001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2001220001.